drugset / Trial / NCT03747341

Buprenorphine-Fentanyl Interaction Study

NCT03747341

Phase 1 Completed 22 enrolled Indivior Inc.
RandomizedCrossoverSingle-blindPrevention

Summary

An increase in overdose deaths has been attributed to widespread access to fentanyl and carfentanyl. The study is designed to determine if buprenorphine can change the respiratory depression response to intravenous (IV) fentanyl.

Timeline

Start
2018-03-22
Primary completion
2019-01-04
Completion
2019-01-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Buprenorphine Other / unclassified 0.000285714 mg/kg Intravenous
Subject Buprenorphine Other / unclassified 0.000714286 mg/kg Intravenous
Subject Buprenorphine Other / unclassified 0.00142857 mg/kg Intravenous
Subject Buprenorphine Other / unclassified 0.00285714 mg/kg Intravenous
Subject Buprenorphine Other / unclassified 0.00714286 mg/kg Intravenous
Subject Fentanyl Other / unclassified 0.00107143 mg/kg Intravenous
Subject Fentanyl Other / unclassified 0.00214286 mg/kg Intravenous
Subject Fentanyl Other / unclassified 0.00357143 mg/kg Intravenous
Subject Fentanyl Other / unclassified 0.005 mg/kg Intravenous
Subject Fentanyl Other / unclassified 0.00714286 mg/kg Intravenous
Subject Fentanyl Other / unclassified 0.01 mg/kg Intravenous
Background Ondansetron Other / unclassified 4 mg Other
Background Oxycodone Other / unclassified Oral